Related references
Note: Only part of the references are listed.Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN
Chad C. Bjorklund et al.
LEUKEMIA (2020)
A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity
Jiye Liu et al.
LEUKEMIA (2019)
Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma
Konstantinos Dimopoulos et al.
LEUKEMIA & LYMPHOMA (2019)
Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4
Yuan Xiao Zhu et al.
BLOOD CANCER JOURNAL (2019)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
Phoebe A. Huang et al.
SCIENTIFIC REPORTS (2019)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Michel Attal et al.
LANCET (2019)
A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies
Drew W. Rasco et al.
CLINICAL CANCER RESEARCH (2019)
Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients
Laurens E. Franssen et al.
HAEMATOLOGICA (2018)
Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients
Laurens E. Franssen et al.
HAEMATOLOGICA (2018)
Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4(CRBN) activity
Quinlan L. Sievers et al.
BLOOD (2018)
Tumor Necrosis Factor Receptor-Associated Factor Regulation of Nuclear Factor κB and Mitogen-Activated Protein Kinase Pathways
Jian-Hong Shi et al.
FRONTIERS IN IMMUNOLOGY (2018)
The proteasome and proteasome inhibitors in multiple myeloma
Sara Gandolfi et al.
CANCER AND METASTASIS REVIEWS (2017)
p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma
Teru Hideshima et al.
BLOOD (2017)
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment
Paul G. Richardson et al.
BLOOD (2016)
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
K. Martin Kortum et al.
BLOOD (2016)
A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
Mary E. Matyskiela et al.
NATURE (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma
Guellue Goerguen et al.
CLINICAL CANCER RESEARCH (2015)
Panobinostat for the Treatment of Multiple Myeloma
Jacob P. Laubach et al.
CLINICAL CANCER RESEARCH (2015)
High-throughput functional genomics using CRISPR-Cas9
Ophir Shalem et al.
NATURE REVIEWS GENETICS (2015)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
H. M. Lokhorst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma
Yuan Xiao Zhu et al.
BLOOD (2014)
High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells
Yuexin Zhou et al.
NATURE (2014)
Improved vectors and genome-wide libraries for CRISPR screening
Neville E. Sanjana et al.
NATURE METHODS (2014)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Kroenke et al.
SCIENCE (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu et al.
SCIENCE (2014)
High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance
Annemiek Broyl et al.
BLOOD (2013)
High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
Daniel Heintel et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma
Yuan Xiao Zhu et al.
LEUKEMIA & LYMPHOMA (2013)
Multiplex Genome Engineering Using CRISPR/Cas Systems
Le Cong et al.
SCIENCE (2013)
Bone Marrow Microenvironment in Multiple Myeloma Progression
S. Manier et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2012)
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
A. Lopez-Girona et al.
LEUKEMIA (2012)
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
Philip L. McCarthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Targeted Genome Editing Across Species Using ZFNs and TALENs
Andrew J. Wood et al.
SCIENCE (2011)
Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2
Sergio E. Alvarez et al.
NATURE (2010)
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito et al.
SCIENCE (2010)
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Martha Q. Lacy et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Shedding light on an old mystery -: Thalidomide suppresses survival pathways to induce limb defects
Juergen Knobloch et al.
CELL CYCLE (2008)
IRF4 addiction in multiple myeloma
Arthur L. Shaffer et al.
NATURE (2008)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Meletios Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma
Jonathan J. Keats et al.
CANCER CELL (2007)
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Teru Hideshima et al.
NATURE REVIEWS CANCER (2007)
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor
Tammie C. Yeh et al.
CLINICAL CANCER RESEARCH (2007)
Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment
Yu-Tzu Tai et al.
CANCER RESEARCH (2006)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway
R LeBlanc et al.
BLOOD (2004)
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
N Mitsiades et al.
BLOOD (2002)
NF-κB as a therapeutic target in multiple myeloma
T Hideshima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2
XM Li et al.
NATURE (2002)
Biologic sequelae of interleukin-6 induced P13-K/Akt signaling in multiple myeloma
T Hideshima et al.
ONCOGENE (2001)
The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma:: therapeutic applications
T Hideshima et al.
ONCOGENE (2001)
Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma
O Sezer et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2001)
Share Paper
